BLA 761081 · Pfizer INC
Trazimera
Trastuzumab-Qyyp · Injection · HER2/neu Receptor Antagonist
Last checked: Nov 20, 2026Latest source record: Aug 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Mar 11, 2019
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
1,500
287 Phase 3, 274 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Trastuzumab" as an intervention, any sponsor and status, largest first.
- ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00490139 · 8,381 participants · Start May 16, 2007 · Primary completion Dec 6, 2013
Drug: Lapatinib; Trastuzumab · For: Neoplasms, Breast
Sites: Mobile, Alabama; Anchorage, Alaska; Tucson, Arizona · 924 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00045032 · 5,099 participants · Start Nov 2001 · Primary completion Mar 2005
Drug: Herceptin; Herceptin · For: Breast Cancer
Sites: Buenos Aires, Argentina; Geelong, Australia; Toowoomba, Australia · 203 sites in all
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01358877 · 4,804 participants · Start Nov 8, 2011 · Primary completion Dec 19, 2016
Drug: 5-Fluorouracil; Carboplatin and 8 more · For: Breast Cancer
Sites: Scottsdale, Arizona; Everett, California; Greenbrae, California · 546 sites in all
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
- Trastuzumab in Treating Women With HER2-Positive Early Breast CancerPivotal-lookingStatus unknown
Warwick Medical SchoolAcademic, hospital or other
NCT00712140 · 4,000 participants (planned) · Start Oct 2007 · Primary completion Oct 2011
Drug: trastuzumab; parenteral chemotherapy · For: Breast Cancer
Sites: Cambridge, United Kingdom; Carlisle, United Kingdom; Derby, United Kingdom · 11 sites in all
- BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus BevacizumabPivotal-lookingTerminated
NSABP Foundation IncResearch network
NCT00625898 · 3,509 participants · Start Apr 2008 · Primary completion Jun 2013
Drug: Docetaxel; Trastuzumab and 5 more · For: Breast Cancer
Sites: Birmingham, Alabama; Decatur, Alabama; Huntsville, Alabama · 649 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Trazimera (Trastuzumab-Qyyp)
2024 spending
$11.4M
Beneficiaries
410
2,939 claims
Per beneficiary
$27,819
$1,813.79 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $62,616 |
| 2021 | $843,987 |
| 2022 | $2,940,701 |
| 2023 | $5,125,689 |
| 2024 | $11,405,691 |
Part B: Trazimera (Trastuzumab-Qyyp) · HCPCS Q5116
2024 spending
$18.6M
Beneficiaries
3,915
28,753 claims
Per beneficiary
$4,753
2024 ASP limit $15.24 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $11,199,931 |
| 2021 | $59,996,202 |
| 2022 | $63,971,431 |
| 2023 | $39,207,374 |
| 2024 | $18,608,786 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
Tolaney SM, Jiang Z, Zhang Q, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Equivalence Trial
- Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
Bardia A, Hu X, Dent R, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Multicenter Study
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Comparative Study
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Comparative Study
- Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.
Shitara K, Van Cutsem E, Gümüş M, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.